Individual patient data analysis to assess modifications to the RECIST criteria

被引:158
作者
Bogaerts, Jan [1 ]
Ford, Robert [2 ]
Sargent, Dan [3 ]
Schwartz, Lawrence H. [4 ]
Rubinstein, Larry [5 ]
Lacombe, Denis [1 ]
Eisenhauer, Elizabeth [6 ]
Verweij, Jaap [7 ]
Therasse, Patrick [8 ]
机构
[1] EORTC Headquarters, B-1200 Brussels, Belgium
[2] RadPharm, Princeton, NJ USA
[3] Mayo Clin, Rochester, MN USA
[4] MSKCC, New York, NY USA
[5] NCI, Bethesda, MD 20892 USA
[6] Natl Canc Inst Canada, Clin Trials Grp, Kingston, ON, Canada
[7] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[8] GlaxoSmithKline Biol, Rixensart, Belgium
关键词
Tumour measurements; RECIST; Response; Progression; METASTATIC-BREAST-CANCER; CELL LUNG-CANCER; PHASE-III TRIAL; 1ST-LINE CHEMOTHERAPY; EUROPEAN-ORGANIZATION; INTRAOBSERVER VARIABILITY; COLORECTAL-CANCER; SOLID TUMORS; DOXORUBICIN; PACLITAXEL;
D O I
10.1016/j.ejca.2008.10.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: After the initial RECIST 1.0 were published in 2000, the criteria were widely implemented in the scientific oncology community. Since then, the RECIST working group has identified several issues to examine further. Two key issues that required careful, data-based assessment were the maximum number of lesions that should be assessed at each evaluation and the added value of requiring confirmation of response. Methods: To address these questions, data were obtained from 16 clinical trials in metastatic cancer, with patients enrolled between 1993 and 2005. A total of 6512 patients were included in the primary analysis dataset, accounting for over 18,000 potential target lesions. Nine percent of the included patients (n = 585) had six or more reported target lesions. The response and progression outcomes in the database were calculated using an adjusted RECIST methodology with a maximum of 5 (or 3) target lesions with/without confirmation and this was compared to the original RECIST version 1.0 which required up to 10 target lesions plus confirmation of response. Results: Assessment of 5 lesions per patient led to a difference in best overall response assignment for an estimated 209 (3.2%) patients as compared to RECIST version 1.0. However, these changes did not affect the overall response rate. Progression-free survival was only minimally affected by measuring fewer lesions. In contrast, removing the requirement for response confirmation led to a significant increase in the numbers of patients classified as responders, resulting in a relative increase of approximately 19% in response rate. An algorithm using a maximum of three target lesions shows high concordance with the 10 lesions requirement in terms of response and TTP assignment. Concern that appropriate assessment of disease within an organ requires two lesions to be followed per organ suggests the approach of following two target lesions per organ, up to a maximum of five target lesions overall. Both strategies seem reasonable based on the data warehouse. The requirement of response confirmation in trials where this is a primary end-point is recommended to be maintained as its removal would substantially increase reported response rates. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:248 / 260
页数:13
相关论文
共 28 条
[1]  
[Anonymous], 2002, P AM SOC CLIN ONCOL
[2]   Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial [J].
Biganzoli, L ;
Cufer, T ;
Bruning, P ;
Coleman, R ;
Duchateau, L ;
Calvert, AH ;
Gamucci, T ;
Twelves, C ;
Fargeot, P ;
Epelbaum, R ;
Lohrisch, C ;
Piccart, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) :3114-3121
[3]   Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a dutch community setting trial for the clinical trial group of the comprehensive cancer centre [J].
Bontenbal, M ;
Creemers, GJ ;
Braun, HJ ;
de Boer, AC ;
Janssen, JT ;
Leys, RB ;
Ruit, JB ;
Goey, SH ;
van der Velden, PC ;
Kerkhofs, LG ;
Schothorst, KL ;
Schmitz, PI ;
Bokma, HJ ;
Verweij, J ;
Seynaeve, C .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7081-7088
[4]  
Casali PG, 2006, J CLIN ONCOL, V24, p523S
[5]   Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer [J].
Chan, S ;
Friedrichs, K ;
Noel, D ;
Pintér, T ;
Van Belle, S ;
Vorobiof, D ;
Duarte, R ;
Gil, MG ;
Bodrogi, I ;
Murray, E ;
Yelle, L ;
von Minckwitz, G ;
Korec, S ;
Simmonds, P ;
Buzzi, F ;
Mancha, RG ;
Richardson, G ;
Walpole, E ;
Ronzoni, M ;
Murawsky, M ;
Alakl, M ;
Riva, A ;
Crown, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2341-2354
[6]   Recommendations for the assessment of progression in randomised cancer treatment trials [J].
Dancey, J. E. ;
Dodd, L. E. ;
Ford, R. ;
Kaplan, R. ;
Mooney, M. ;
Rubinstein, L. ;
Schwartz, L. H. ;
Shankar, L. ;
Therasse, P. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :281-289
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]   Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response [J].
Erasmus, JJ ;
Gladish, GW ;
Broemeling, L ;
Sabloff, BS ;
Truong, MT ;
Herbst, RS ;
Munden, RF .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2574-2582
[9]   Lessons learned from independent central renew [J].
Ford, R. ;
Schwartz, L. ;
Dancey, J. ;
Dodd, L. E. ;
Eisenhauer, E. A. ;
Gwyther, S. ;
Rubinstein, L. ;
Sargent, D. ;
Shankar, L. ;
Therasse, P. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :268-274
[10]   Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial [J].
Gatzemeier, Ulrich ;
Pluzanska, Anna ;
Szczesna, Aleksandra ;
Kaukel, Eckhard ;
Roubec, Jaromir ;
De Rosa, Flavio ;
Milanowski, Janusz ;
Karnicka-Mlodkowski, Hanna ;
Pesek, Milos ;
Serwatowski, Piotr ;
Ramlau, Rodryg ;
Janaskova, Terezie ;
Vansteenkiste, Johan ;
Strausz, Janos ;
Manikhas, Georgy Moiseevich ;
Von Pawel, Joachim .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1545-1552